Xenetic Biosciences, Inc. (NASDAQ:XBIO)

BRIEF

published on 03/13/2025 at 13:35, 16 hours 13 minutes ago

Xenetic Biosciences Reveals Promising Preclinical Data for DNase I in Cancer Therapy

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Therapy CAR T Cells
PRESS RELEASE

published on 03/13/2025 at 13:30, 16 hours 18 minutes ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Xenetic Biosciences presents promising findings on combining DNase I with CAR T cells to enhance cancer treatment strategies at the SITC Spring Scientific 2025 Cell Therapy Meeting

Xenetic Biosciences Cancer Treatment DNase I CAR T Cells SITC Spring Meeting
BRIEF

published on 02/27/2025 at 15:20, 14 days 14 hours ago

Xenetic Biosciences' Abstract Accepted for SITC 2025 Meeting

Xenetic Biosciences Immuno-oncology Cell Therapy DNase Platform SITC 2025
PRESS RELEASE

published on 02/27/2025 at 15:15, 14 days 14 hours ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Xenetic Biosciences announces abstract acceptance for SITC Spring Scientific 2025 Cell Therapy Meeting on targeting Neutrophil Extracellular Traps in Metastatic Melanoma

Xenetic Biosciences DNase Platform Poster Presentation Immuno-oncology Technologies SITC Spring Scientific 2025
BRIEF

published on 12/17/2024 at 15:20, 2 months 27 days ago

Xenetic Biosciences Extends Research Agreement with University of Virginia

Xenetic Biosciences University Of Virginia Cancer Treatment DNase Platform Immune-oncology
PRESS RELEASE

published on 12/17/2024 at 15:15, 2 months 27 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Xenetic extends Research Agreement with University of Virginia for DNase-Based oncology platform. Dr. Reid Bissonnette discusses the advancement of innovative immune-oncology technologies

University Of Virginia Xenetic Research Agreement DNase-Based Oncology Platform
BRIEF

published on 12/16/2024 at 15:05, 2 months 28 days ago

Xenetic Biosciences Extends Research Agreement with UVA for DNase Oncology Platform

Xenetic Biosciences University Of Virginia Immunotherapy DNase Oncology NETs
PRESS RELEASE

published on 12/16/2024 at 15:00, 2 months 28 days ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences extends Research Funding Agreement with UVA to develop systemic DNase program targeting NETs to improve cancer therapy outcomes

Xenetic Biosciences DNase Program Cancer Therapy Immunotherapy NETs
BRIEF

published on 12/05/2024 at 14:50, 3 months 8 days ago

Xenetic Biosciences Partners with PeriNess for Clinical Trial Services

Xenetic Biosciences Clinical Trials Oncology DNase I PeriNess Ltd.
PRESS RELEASE

published on 12/05/2024 at 14:45, 3 months 8 days ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I

1 2 ... 4

Published on 03/13/2025 at 21:30, 8 hours 18 minutes ago

Star Royalties Highlights Copperstone Project Economics and Stream Valuation
Published on 03/13/2025 at 21:30, 8 hours 18 minutes ago

Relevant Gold Closes Second Tranche of Upsized $8.5 Million Non-Brokered Private Placement Led by Strategic Investors Kinross and Bollinger
Published on 03/13/2025 at 21:28, 8 hours 20 minutes ago

Zomedica Reports Record Revenue of $7.9 Million for the Fourth Quarter and $27.3 Million for the Full Year 2024; 70% Gross Margin, and $71 Million in Liquidity to Support Growth
Published on 03/13/2025 at 21:20, 8 hours 28 minutes ago

Fresh Vine Wine, Inc. To Change Corporate Name To Amaze Holdings, Inc. and Ticker Symbol to AMZE Following Strategic Acquisition
Published on 03/13/2025 at 21:15, 8 hours 33 minutes ago

Kingstone Reports Record Fourth Quarter and Full Year 2024 Results

View all ACCESSWIRE

Published on 03/13/2025 at 20:58, 8 hours 49 minutes ago

EQS-Adhoc: Deutsche Konsum REIT-AG: Deutsche Konsum REIT concludes bridge financing agreement. Changes in the Supervisory Board.
Published on 03/13/2025 at 19:49, 9 hours 59 minutes ago

EQS-Adhoc: ABO Energy GmbH & Co. KGaA increases forecast
Published on 03/13/2025 at 18:30, 11 hours 18 minutes ago

Swiss Prime Site: Annual General Meeting approves all proposals of the Board of Directors with a large majority
Published on 03/13/2025 at 17:55, 11 hours 53 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 03/13/2025 at 17:45, 12 hours 3 minutes ago

FIGEAC AÉRO: FIGEAC AÉRO INVESTS IN THE INDUSTRY OF THE FUTURE WITH THE SUPPORT OF FRANCE 2030 AND THE DGAC

View all EQS

Published on 03/13/2025 at 19:30, 10 hours 18 minutes ago

CDA - Sharholder Meeting report - March 13
Published on 03/13/2025 at 18:00, 11 hours 48 minutes ago

Air Liquide has successfully issued a 500 million euros green bond to finance the energy transition
Published on 03/13/2025 at 17:45, 12 hours 3 minutes ago

Press release Directors Board 13.03.2025
Published on 03/13/2025 at 17:45, 12 hours 3 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2025
Published on 03/13/2025 at 08:33, 21 hours 14 minutes ago

Safran - Update OCEANE 2028

View all LES ECHOS COMFI WIRE

News